New Delhi, Dec. 18 -- Sun Pharma share price fell over 3% to Rs.1,738 apiece on NSE in Thursday's trading session after the US Food and Drug Administration designated the company's Baska manufacturing facility as Official Action Indicated (OAI).

According to an exchange filing, the pharma major said the inspection took place between September 8 and September 19, 2025, following which the US FDA classified the facility under Official Action Indicated (OAI) status.

"This is to inform that the US FDA inspected the Company's Baska facility from 8 September 2025 to 19 September 2025. The US FDA has subsequently determined that the inspection classification status of this facility is Official Action Indicated (OAI)," the company said in the f...